Invited Reviews  CME

Challenges and Opportunities for Preexposure Prophylaxis  CME  399
Mary Catherine Cambou, MD; Raphael J. Landovitz, MD, MSc
Oral Tenofovir Disoproxil Fumarate/Emtricitabine • Oral Tenofovir Alafenamide/Emtricitabine • Moving to Next-Generation PrEP or “PrEP 2.0” • Injectable Cabotegravir • Islatravir • Lenacapavir

HIV and Cardiovascular Disease: From Insights to Interventions  CME  407
Matthew J. Feinstein, MD, MSc
Epidemiology of HIV-Associated Cardiovascular Diseases • Mediators of Atherosclerosis and Thrombosis in HIV • Mechanisms and Presentation of HIV-Associated Heart Failure • Cardiovascular Disease Risk Stratification, Prevention, and Therapy for Individuals With HIV

Perspective

Primary Care Concerns for the Aging Population With HIV  CME  412
Steven C. Johnson, MD
Cancer Screening • Immunizations
Topics in Antiviral Medicine™

Topics in Antiviral Medicine™ (formerly Topics in HIV Medicine) is published by the International Antiviral Society–USA (IAS–USA). This journal is intended to be a resource for practitioners and scientists who are actively involved in medical care and research in HIV and other viral infections.

Editorial Policy
The views and opinions expressed in this journal are those of the contributors and do not necessarily reflect the views or recommendations of the IAS–USA. Topics in Antiviral Medicine™ is supported through grants from several commercial companies that are committed to supporting continuing medical education on HIV, hepatitis C virus, and other viral infections. In the interest of an objective, balanced, and scientifically rigorous publication, the IAS–USA seeks funding that is pooled from companies with competing products; these companies have no input or control over the journal content or the selection of contributors.

This journal may contain information about the investigative uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in Topics in Antiviral Medicine™.

Copyrights and Reprint
The contents of Topics in Antiviral Medicine™ are protected by copyright. We welcome reference to and use of portions of this journal; however, we do require that permission to reproduce or use any part of the journal be obtained from the IAS–USA.

In the case of reprinted or adapted materials where the IAS–USA does not own the copyright, permission to reproduce these materials must be obtained directly from the original source. For more information about reprints, please send an email to journal@iasusa.org.

Subscription Information
Topics in Antiviral Medicine™ is published 4 to 6 times a year. To obtain a subscription or notify the IAS–USA of a change in your email address, please create or update your user profile at www.iasusa.org.

Correspondence
Topics in Antiviral Medicine™ welcomes editorial correspondence. Address correspondence to:
Editor, Topics in Antiviral Medicine™
Email: journal@iasusa.org
Mail: IAS–USA
131 Steuart St, Ste 500
San Francisco, CA 94105
Phone: (415) 544-9400
Website: www.iasusa.org

On the Web
Current and previous issues of Topics in Antiviral Medicine™ (as well as Topics in HIV Medicine) are available online at www.iasusa.org.
ISSN 2161-5853 (Online)
©2021 IAS–USA. All rights reserved

Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies (formerly described as commercial interests by ACCME). Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

SILVER SUPPORTER
Janssen Therapeutics

BRONZE SUPPORTER
Theratechnologies, Inc.
Invited Reviews

Challenges and Opportunities for Preexposure Prophylaxis
Mary Catherine Cambou, MD; Raphael J. Landovitz, MD, MSc
399

HIV and Cardiovascular Disease: From Insights to Interventions
Matthew J. Feinstein, MD, MSc
407

Perspective

Primary Care Concerns for the Aging Population With HIV
Steven C. Johnson, MD
412

Announcements

Continuing Medical Education (CME) Information
398
Guidelines for Authors and Contributors
416

Visit www.iasusa.org/activities/topics-in-antiviral-medicine or use the QR code in this issue to access the online posttest.
The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

The IAS–USA designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from November 30, 2021, to November 30, 2022. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Others will receive a certificate of participation. Visit www.iasusa.org for information on the posttest and evaluation for this activity.

- CME credits available: 1.75 AMA PRA Category 1 Credits™
- Release date: November 30, 2021
- Expiration date: November 30, 2022

**Learning Objectives**

On completion of this activity, which contains 3 articles, the learner will be able to:

- Describe additional choices of HIV prevention strategies beyond daily oral TDF/FTC
- Identify how to optimally predict, prevent, and treat cardiovascular diseases among individuals with HIV
- Describe the comorbidities that are of primary concern for older adults with HIV

**Intended Audience**

This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

**Conflicts of Interest**

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.

All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with ineligible companies (formally known as "commercial interests") within the past 24 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines an ineligible company as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible companies.” The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with ineligible companies, enabling the audience members to form their own judgments about such associations.

The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for contributors and planners/reviewers is below. Information about financial relationships with ineligible companies for contributors and planners/reviewers is below. Information about financial relationships with ineligible companies for contributors is also included in each article.

**Contributors**

Dr Cambou has no relevant financial relationships with ineligible companies to disclose. (Updated on November 15, 2021)

Dr Landovitz has served on scientific advisory boards for Gilead Sciences, Inc, and Merck & Co, Inc. (Updated on November 15, 2021)

Dr Feinstein has received advisory board fees from Novartis AG. (Updated on September 27, 2021)

Dr Johnson has served on an advisory board for and received consultation fees to his institution from ViiV Healthcare. (Updated on November 23, 2021)

**Planners/Reviewers**

Planner/reviewer 1 has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Merck and Co, Inc. (Updated on December 3, 2021)

Planner/reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated on November 30, 2021)

Reviewer 3 has no relevant financial relationships with ineligible companies to disclose. (Updated on December 3, 2021)

**Drug and Product Disclaimer**

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of the contributors and do not necessarily represent the opinions or recommendations of the IAS–USA.

---

Independent educational grants for the 2021 Improving the Management of HIV Disease® CME program:

**PLATINUM SUPPORTERS**

- Gilead Sciences, Inc.
- Merck and Co, Inc.
- ViiV Healthcare

**SILVER SUPPORTER**

- Janssen Therapeutics

**BRONZE SUPPORTER**

- Theratechnologies, Inc.
Invited Review

Challenges and Opportunities for Preexposure Prophylaxis

Mary Catherine Cambou, MD; Raphael J. Landovitz, MD, MSc

Despite major advances in the HIV prevention toolbox in the past decade, there remain substantial social, economic, and structural barriers to access to preexposure prophylaxis (PrEP) that prevent a universal, population-level reduction in HIV incidence. Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) has been the flagship PrEP regimen, and data support a pericoital-demand “2-1-1” dosing schedule for men who have sex with men. Daily oral PrEP with tenofovir alafenamide combined with emtricitabine (TAF/FTC) was approved by the US Food and Drug Administration (FDA) in 2019 for all routes of exposure other than vaginal exposures. The effectiveness of daily oral TDF/FTC has not been consistent in cisgender women outside of serodifferent couples, likely owing to differences in vaginal tissue penetration of PrEP agents resulting in less “forgiveness” of nonadherence. These observations have highlighted the need for additional choices of HIV prevention strategies. Injectable long-acting cabotegravir was recently shown to be superior to daily oral TDF/FTC across risk populations. PrEP studies of islatravir are underway for a monthly formulation and a drug-eluting subdermal implant. Lenacapavir, with a novel mechanism of action, is under investigation as a subcutaneous injection at 6-month intervals.

Keywords: HIV prevention, PrEP, long-acting PrEP, cabotegravir, injectable PrEP, islatravir, lenacapavir, dapivirine

Introduction

Despite major advances in HIV prevention in the past decade, and data supporting the extraordinary potential of preexposure prophylaxis (PrEP), many barriers remain that hamper the access and scale-up required to attain population-level benefits. An estimated 1.7 million incident HIV infections every year worldwide highlight the need for increased access and additional options for HIV prevention. To end the HIV epidemic globally, new PrEP formulations and delivery systems that increase acceptability, adherence, and persistence, while reducing stigma, costs, and barriers to use by all populations, will be required. Although the data to support oral tenofovir disoproxil fumarate (TDF) plus emtricitabine (TDF/FTC) as PrEP revolutionized HIV chemoprophylaxis, the dapivirine vaginal ring (DPV-VR), tenofovir alafenamide (TAF)/emtricitabine (TAF/FTC), injectable long-acting cabotegravir (CAB-LA), monthly oral and subdermally implanted islatravir, and long-acting subcutaneous lenacapavir are all currently under investigation as PrEP options.

Oral Tenofovir Disoproxil Fumarate/Emtricitabine

In 2010, the iPrEx (Pre-Exposure Prophylaxis Initiative) study was the first phase III, double-blind, randomized control trial (RCT) to demonstrate the efficacy and safety of daily oral TDF/FTC for the prevention of HIV acquisition among cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men. Globally, 2499 HIV-negative participants were enrolled, and 100 participants acquired HIV during the study period: 36 versus 64 in the TDF/FTC versus placebo arm, respectively (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.37-0.85; *P* <.005 in the modified intention-to-treat analysis). In a subanalysis, plasma and peripheral blood mononuclear cells (PBMCs) from active TDF/FTC-arm participants were tested for their metabolites and the study drug. Detectable study-drug concentrations were associated with a relative reduction in HIV risk by 92% (95% CI, 40-99; *P* <.001), underscoring the importance of study product use and highlighting the challenges of adhering to a daily oral PrEP regimen.

In a separate analysis, PBMC tenofovir diphosphate concentrations from the active iPrEx-arm participants were compared with the concentrations from HIV-negative participants who were administered TDF/FTC in directly observed doses 2, 4, or 7 times per week. Extrapolating those dosing concentrations to iPrEx participants in whom TDF/FTC achieved comparable concentrations, 7 doses per week was associated with a 99% risk reduction, with 96% and 76% risk reduction estimates for 4 and 2 doses per week, respectively, compared with placebo-arm risk. These results suggest a relatively high level of “forgiveness” to nonadherence for genital exposures, with 4 or more doses per week still conferring high levels of protection. This observation was further supported by the iPrEx Open-Label Extension study, which also supported high levels of protection against rectal HIV acquisition with 4 or more doses per week on average, using intraerythrocytic tenofovir diphosphate.
levels measured in dried blood spots (DBSs). The following year, the results of the Partners PrEP Study demonstrated the safety and efficacy of daily oral TDF/FTC as PrEP among heterosexual, HIV-1 serodifferent couples in Uganda and Kenya. The HIV-negative partner within each of 4747 couples was randomly assigned to TDF, TDF/FTC, or placebo. Over a 5-year period, 82 HIV-1 infections occurred among the participants: 17 in the TDF arm, 13 in the TDF/FTC arm, and 52 in the placebo arm, representing a 75% relative reduction of HIV-1 acquisition in the TDF/FTC arm (95% CI, 55%-87%, P < .001). In 2012, the US Food and Drug Administration (FDA) approved daily oral TDF/FTC for PrEP for HIV-negative adults at high risk of HIV-1 seroconversion, based largely on the results of the iPrEx, Partners PrEP, and TDF2 (Botswana TDF/FTC Oral HIV Prophylaxis Trial) studies.

In 2015, the results of the IPERGAY (Intervention Préventive de l’Exposition aux Risques avec et pour les Gays) study were published; IPERGAY was a double-blind RCT designed to evaluate the efficacy of pericoital TDF/FTC versus placebo in MSM in France and Canada. The study’s dosing schedule generated the nickname for the regimen, 2-1-1, and consisted of a loading dose of 2 TDF/FTC tablets 2 to 24 hours prior to planned sex and 1 pill each at 24 and 48 hours after the first dose. Among 400 participants, the incidence of HIV-1 seroconversion was 0.91 per 100 person-years in the TDF/FTC arm (2 cases), compared with 6.6 per 100-person years in the placebo arm (14 cases), representing a risk reduction of 86% (95% CI, 40%-98%; P = .002). Participants in the TDF/FTC arm took a median of 15 pills per month (interquartile range [IQR], 11-21), consistent with the findings of the iPrEx and iPrEx Open-Label Extension studies, demonstrating that at least 4 daily doses of TDF/FTC per week was highly protective against HIV-1 seroconversion. Follow-up analyses of IPERGAY participants with fewer median PrEP courses taken had consistent findings of high levels of HIV protection. Although the FDA has not approved TDF/FTC for on-demand dosing, the International Antiviral Society–USA (IAS–USA) and the World Health Organization (WHO) recommend the on-demand 2-1-1 schedule as an alternative to daily oral TDF/FTC for MSM.

Table. Comparison of Selected PrEP Agents

<table>
<thead>
<tr>
<th>PrEP agent</th>
<th>Route of administration</th>
<th>Phase of development</th>
<th>FDA approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF/FTC</td>
<td>Oral</td>
<td>III</td>
<td>Yes</td>
</tr>
<tr>
<td>On-demand TDF/FTC</td>
<td>Oral</td>
<td>III</td>
<td>No – recommended by IAS–USA and the WHO for use in cisgender MSM</td>
</tr>
<tr>
<td>TAF/FTC</td>
<td>Oral</td>
<td>III</td>
<td>Yes – in cisgender MSM and TGW</td>
</tr>
<tr>
<td>Dapivirine</td>
<td>Monthly vaginal ring</td>
<td>III</td>
<td>No – recommended by the EMA and WHO for use in cisgender women in high-prevalence regions</td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>Intramuscular injection every 8 weeks</td>
<td>III</td>
<td>No – under review at the FDA for PrEP. Approved for treatment of HIV-1 infection in combination with rilpivirine in virologically suppressed patients</td>
</tr>
<tr>
<td>Islatravir</td>
<td>Oral, subdermal implant</td>
<td>III</td>
<td>No</td>
</tr>
<tr>
<td>Lenacapavir</td>
<td>Oral, subcutaneous injection every 6 months</td>
<td>III</td>
<td>No</td>
</tr>
</tbody>
</table>

Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; IAS–USA, International Antiviral Society–USA; MSM, men who have sex with men; PrEP, preexposure prophylaxis; TAF/FTC, tenofovir alafenamide/emtricitabine; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine; TGW, transgender women; WHO, World Health Organization.

Although TDF/FTC has performed consistently well as PrEP for MSM and serodifferent heterosexual couples, studies among cisgender women have been inconsistent. The FEM-PrEP (Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-Exposure Prophylaxis) study, a double-blind RCT among 2120 HIV-negative women in South Africa, Tanzania, and Kenya, found no significant difference between incidence rates in the TDF/FTC group and the placebo group (4.7 per 100 person-years vs 5.0 per 100 person-years; HR, 0.94; 95% CI, 0.59-1.52). Fewer than 40% of participants in the TDF/FTC arm had plasma evidence of recent study product dosing, highlighting the lesser “forgiveness” of TDF/FTC PrEP to nonadherence in the setting of vaginal exposures. The VOICE (Vaginal and Oral Interventions to Control the Epidemic) study, a placebo-controlled, randomized trial to assess oral TDF/FTC, oral TDF, or 1% tenofovir vaginal gel as PrEP agents among 12,320 cisgender women in sub-Saharan Africa, found that none of the investigational regimens reduced the risk of HIV-1 acquisition compared with placebo. It is challenging to distinguish how much of the reduced efficacy for vaginal sex is attributable to drug tissue levels and how much to differential adherence, but it is clear from the Partners PrEP study that high levels of protection are possible with rigorous adherence. These findings, and the companion qualitative work, suggest that risk perception, competing priorities, stigma, and fear of intimate partner violence may have compromised pill-taking (and gel use), encouraging ongoing research into additional PrEP agents and delivery systems that could minimize these concerns and support adherence.

**Oral Tenofovir Alafenamide/Emtricitabine**

Although generally very safe, concerns about potential renal toxicity and loss of bone mineral density on dual-energy X-ray absorptiometry (DEXA) scanning attributable to TDF-based PrEP inspired the DISCOVER (Study to Evaluate the...
Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection trial, a double-blind, phase III, noninferiority trial comparing TAF/FTC with TDF/FTC in cisgender MSM and TGW. More than 5380 participants in the United States, Canada, and Europe were randomly assigned to daily oral TAF/FTC or TDF/FTC in a double-blinded RCT. In the primary analysis, there were 7 seroconversions in the TAF/FTC group (0.16 infections per 100 person-years) compared with 15 in the TDF/FTC group (0.34 infections per 100 person-years). The incidence rate ratio (IRR) of 0.47 (95% CI, 0.19-1.15) was consistent with a noninferiority statistical result. Although sensitive laboratory renal biomarkers and bone mineral density were better in the TAF/FTC group than in the TDF/FTC group, there were no significant differences in clinical outcomes between the 2 arms, though there was an average weight gain of 1 kg in the TAF/FTC group, and no net weight change in the TDF/FTC group. There was also a small (1 mg/dL) increase in fasting low-density lipoprotein cholesterol level in the TAF/FTC group, compared with a 6.5 mg/dL decrease in fasting low-density lipoprotein level in the TDF/FTC group. The FDA approved TAF/FTC for PrEP in 2019, but it did not extend the approval to those who engage in receptive vaginal intercourse.

Moving to Next-Generation PrEP or “PrEP 2.0”

Stigma around taking a daily medication associated with and potentially confused with HIV treatment has been cited as a potential barrier to PrEP adherence. Discrete delivery mechanisms, including vaginal rings, injectable medications, and drug-eluting implants, are attractive contenders to expand PrEP options. There is additional ongoing interest in topical gels, foams, threads, and inserts for vaginal or rectal use, as well as microneedle patches to be administered topically.

Dapivirine Vaginal Ring

Vaginal rings have been used successfully for hormonal contraception, making them an appealing option for PrEP for individuals at risk by vaginal exposure, given the structural, social, and environmental barriers to adherence with daily oral TDF/FTC seen in the randomized trials. Dapivirine, a nonnucleoside reverse transcriptase inhibitor (NNRTI) not available as an oral preparation, was tested in a monthly vaginal ring in 2 major phase III, double-blind, randomized trials: the ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) and Ring (Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women) studies. In the ASPIRE study, 2629 cisgender women in South Africa, Uganda, and Zimbabwe were randomly assigned to a 25 mg DPV-VR or placebo ring. Over a median follow-up of 1.6 years (IQR, 1.1-2.3 years), monthly replacement of the DPV-VR compared with placebo reduced the incidence of HIV-1 infection by 27% (P = .046). In the post-hoc adherence analysis stratified by age, the DPV-VR reduced incidence in women over 21 years of age by 56% (P < .001). The results of the Ring study were published the same year, in 2016; among 1959 cisgender women randomly assigned in a 2:1 fashion to the DPV-VR or placebo, monthly use of the DPV-VR reduced the incidence of HIV-1 acquisition by 31% (HR, 0.69; 95% CI, 0.49-0.99; P = .04).

The open-label extensions of the ASPIRE and Ring studies have suggested higher levels of efficacy with more consistent use of the DPV-VR. The MTN (Microbicide Trials Network)-025/HOPE (HIV Open-label Prevention Extension) study was a phase IIb open-label extension of the ASPIRE trial; HIV-negative participants in the original ASPIRE trial were offered 12 months of open-label DPV-VR to evaluate real-world uptake, consistent use, and acceptance outside of an RCT setting. A total of 1456 women were enrolled, and 92.2% of study participants agreed to use the DPV-VR. Most participants reported acceptance of the DPV-VR at each visit, and 89.5% of the rings returned and tested for dapivirine release were consistent with use during the month. The HIV-1 incidence rate was 2.7 per 100 person-years, less than the placebo rate of 4.4 per 100 person-years. Similar results were reported by the DREAM (Determined, Resilient, Empowered, AIDS-free, Mentored and Safe) study, an open-label extension of the Ring study; the residual amount of dapivirine in returned rings was significantly lower in the DREAM study than in the Ring study (suggestive of more consistent use), and the HIV incidence of 1.8 per 100 person years was 62% lower than the simulated placebo rate.

Injectable Cabotegravir

CAB-LA, a novel integrase strand transfer inhibitor (InSTI) administered as an intramuscular gluteal injection every 8 weeks, is an attractive PrEP option for high-risk individuals unable to adhere to a daily oral PrEP formulation, or who may prefer injections to tablets for a variety of reasons, including discretion and convenience. Cabotegravir has been evaluated in 2 phase III clinical trials and is currently pending regulatory review in the United States.

The HIV Prevention Trials Network (HPTN) 083 trial is a double-blind, phase III, noninferiority RCT designed to compare the efficacy and safety profile of CAB-LA with daily oral TDF/FTC in cisgender MSM and TGW. Eligible HIV-negative participants were recruited from sites in Africa, Asia, Latin
A total of 4566 participants were included in the modified intention-to-treat analysis. The study population was diverse; the median age was 26 years, 49.8% of US participants identified as Black, and 12.5% of all participants were TGW. An independent data safety monitoring board (DSMB) recommended that the study be unblinded in May 2020 based on an early efficacy finding: In the cabotegravir arm, there were 13 incident infections (incidence, 0.41 per 100 person-years), and in the TDF/FTC arm, there were 39 incident infections (incidence, 1.22 per 100 person-years), representing a 66% reduction in HIV-1 acquisition (HR, 0.34; 95% CI, 0.18-0.62) for cabotegravir compared with TDF/FTC, meeting statistical superiority.27

In the case of cabotegravir PrEP breakthrough infections, the potent antiviral properties of cabotegravir were found to suppress viremia and delay antibody detection, thus delaying the time to reactivity of conventional, largely antibody-based, diagnostics. Qualitative and quantitative RNA testing were found to be more sensitive than traditional antigen and antibody assays, and such post-hoc testing resulted in a reanalysis of the HPTN 083 primary results to instead contain 12 incident infections in the CAB-LA arm, and an unchanged number (39) in the TDF/FTC arm.

Of the 16 total infections in the CAB-LA arm, 4 were prevalent/baseline (ie, within the window period at enrollment into the study by conventional algorithmic HIV testing), and 12 were incident. These 16 were classified by the investigators into 4 groups: 4 infections occurred prior to enrollment (group A), 5 occurred without recent exposure to CAB-LA (group B), 3 occurred prior to a CAB-LA injection (ie, during the oral lead-in, group C), and 4 infections occurred with expected plasma CAB-LA concentrations based on the timing of the injections (group D). InSTI resistance mutations were detected in 1 group A case, 2 group C cases, and 2 group D cases (Figure 2). In the cases of HIV acquisition during the “tail” phase, resistance was not identified (all were wild type). The 4 group D infections remain incompletely explained; hypotheses for the breakthrough cases include possible lower plasma levels

---

**Figure 1.** HIV Prevention Trials Network 083 trial design. Abbreviations: CAB, cabotegravir; CAB-LA, long-acting cabotegravir; PK, pharmacokinetic; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine. Adapted from Landovitz et al.27
Figure 2. Pharmacologic and virologic data for HIV breakthrough cases in the cabotegravir group from the HIV Prevention Trials Network 083 study. Bold mutations are major mutations in the International Antiviral Society-USA resistance guidelines. See text on page 4 for more context. Abbreviations: BLQ, below the limit of quantification; CAB-LA, long-acting cabotegravir; LLOQ, lower limit of quantitation; PA-IC₉₀, protein-adjusted 90% inhibitory concentration; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine. Adapted from Landovitz et al.27
between the 2 initial injections, low cabotegravir partitioning into rectal tissue, or concomitant rectal inflammation. High-sensitivity assays, such as nucleic-acid–based viral load testing to detect HIV breakthrough as early as possible, are currently being evaluated in an open-label extension to the parent study. These viral load tests would be useful if earlier detection can reduce the probability of InSti resistance, but would pose additional implementation and scale-up challenges.

In the HPTN 083 trial, CAB-LA was generally well tolerated. Most participants in the CAB-LA group (83%) reported an injection site reaction, although most of these were mild or moderate and declined over time with serial injections. Only 2.2% of participants reported a sufficiently severe injection-related event to lead to injection discontinuation. In addition, CAB-LA was associated with an average weight increase of 1.3 kg per year compared with 0.3 kg per year in the TDF/FTC arm.

HPTN 084 is the sister study of HPTN 083; it was a similarly designed double-blind phase III RCT that compared the efficacy of CAB-LA with daily oral TDF/FTC in more than 3200 cisgender women in sub-Saharan Africa. The DSMB also halted the blinded comparison of the HPTN 084 trial early, in November 2020, for CAB-LA’s superiority to daily oral TDF/FTC; there were 4 incident HIV infections in the CAB-LA group (incidence rate, 0.21%) compared with 34 infections in the TDF/FTC group (incidence rate, 1.79%), representing an 89% risk reduction (HR, 0.11; 95% CI, 0.04%-0.32%). Bridging safety, tolerability, and acceptability studies in adolescents are ongoing, as are designated studies for pregnant and breastfeeding people. Cabotegravir as a PrEP agent is currently under review by the FDA.

**Islatravir**

Islatravir is an investigational first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits translocation and results in early chain termination of the viral reverse transcriptase DNA product. PK studies of the oral formulation of islatravir and drug-eluting subdermal implants have demonstrated prolonged plasma and intracellular half-lives and excellent antiviral potency.

There are 2 ongoing phase III blinded RCTs that will evaluate the efficacy and safety of once-monthly oral tablets of islatravir as PrEP: the Impower-022 study among cisgender women at high risk of HIV-1 acquisition in sub-Saharan Africa and the United States, and the Impower-024 study among cisgender MSM and TGW in the United States, France, Japan, and Europe. Both studies started enrollment in early 2021 and are actively recruiting participants. The results of a phase I study to evaluate the islatravir implant were presented at CROI 2021. A total of 36 participants were randomly assigned to a placebo implant or varying doses of the islatravir implant for 3 months. The intracellular half-life was 198 hours following removal of the implant, suggesting maintenance of target concentrations up until 1 year postimplantation, based on triangulation of a macaque challenge model and therapeutic efficacy targets. The majority of participants reported mild adverse effects, although half of the placebo implant group did as well. There were no serious adverse effects requiring discontinuation of the implant. A phase II study to test the highest dose implant formulation is currently underway.

**Lenacapavir**

Previously known as GS-6207, lenacapavir is an investigational first-in-class, long-acting HIV capsid inhibitor available as an oral formulation and as a subcutaneous injection administered every 6 months. Subcutaneous lenacapavir has shown high metabolic stability and antiviral potency in a phase II/III trial of heavily treatment-experienced people with HIV; the addition of lenacapavir to a failing antiretroviral (ARV) regimen among 24 participants resulted in a 1.93 log_{10} copies/mL decline in HIV-1 RNA at day 15, compared with a 0.29 log_{10} copy/mL decline in the placebo group of 12 participants (P < .0001). There were no serious adverse events leading to discontinuation of lenacapavir, and injection site adverse effects were generally mild. The efficacy and safety profile of long-acting lenacapavir make it an attractive option for PrEP as monotherapy. There are currently 2 planned phase III randomized trials to evaluate the efficacy and safety of lenacapavir for PrEP compared with a counterfactual placebo: PURPOSE 1 (Study to Assess Safety and Efficacy of Lenacapavir and Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection) among adolescent girls and young cisgender women at high risk of HIV-1 acquisition, and PURPOSE 2 (Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus Pre-Exposure Prophylaxis) among MSM, TGW, and gender nonbinary people who have condomless receptive anal intercourse. Both studies are open and actively recruiting participants.

**Conclusion**

Novel PrEP formulations and alternative modes of delivery are needed to expand PrEP options for at-risk populations. Drawing from family planning literature, more choices will provide more options that will be acceptable and congruent with the lives of more at-risk individuals. Daily oral TDF/FTC is FDA-approved for PrEP in the United States across risk-populations and in many other countries globally, and TAF/FTC was recently approved in the United States for all routes of exposure except vaginal intercourse. The DVP-VR shows use-dependent results in cisgender women, but it may be acceptable to women who will not or cannot use pill-based HIV prevention strategies; a phase III clinical trial in pregnant people is actively recruiting participants in sub-Saharan Africa. CAB-LA was found to be superior for prevention of HIV-1 acquisition to daily oral TDF/FTC in the HPTN 083 and HPTN 084 trials. Clinical trials of a monthly oral islatravir tablet and a long-acting drug-eluting islatravir...
implant are currently underway. The addition of long-acting lenacapavir monotherapy to failing ART regimens in heavily treatment-experienced people with HIV resulted in a clinically significant and rapid decline in HIV-1 RNA, making it an attractive option for PrEP in at-risk populations.

This article was based, in part, on a webcast presented by Dr Raphael J. Landovitz in May 2021: https://youtu.be/zxf7c99Rqgo. This article was prepared by Dr Cambou and Dr Landovitz in August 2021.

Financial affiliations with ineligible companies (formerly named “commercial interests” by the ACCME) in the past 24 months: Dr Cambou has no relevant financial affiliations by the ACCME) in the past 24 months: Dr Raphael J. Landovitz in the past 24 months: Dr

References


Invited Review

HIV and Cardiovascular Disease: From Insights to Interventions

Matthew J. Feinstein, MD, MSc

Individuals with HIV have elevated risks for cardiovascular diseases (CVDs) ranging from myocardial infarction to heart failure. Our understanding of this heightened HIV-associated cardiovascular risk has evolved over the past 2 decades. In the early era of antiretroviral therapy (ART), concern existed that ART was the primary driver of cardiovascular risk. However, it has become increasingly apparent that HIV-related viremia, immune dysregulation, and inflammation are primary drivers of HIV-associated cardiovascular risk, along with traditional cardiovascular risk factors such as tobacco smoking. Indeed, early and effective ART blunts risk for CVDs among individuals with HIV. Despite these improvements in HIV-associated cardiovascular risk, questions remain regarding how to optimally prevent, treat and CVDs among individuals with HIV. Efforts are underway to define more precisely which diagnostic and therapeutic strategies will be most effective in curbing HIV-associated CVDs.

Keywords: HIV, cardiovascular disease, CVD, inflammation, atherosclerosis, heart failure, myocardial infarction

Individuals with HIV have higher risks for cardiovascular diseases (CVDs), including myocardial infarction (MI), heart failure, and pulmonary hypertension, than individuals without HIV.1-5 As life expectancy has increased for individuals with HIV as a result of effective antiretroviral therapy (ART), the burden of diseases of aging, including CVDs, has increased among individuals with HIV.6-8

There are several reasons for elevated CVD risk among people with HIV that reflect the diverse pathophysiology of CVDs. Diseases of the vasculature, such as MI, occur as a result of a combination of atherosclerosis and thrombosis. Meanwhile, heart failure reflects a final common pathway of different and often overlapping pathophysilogies, ranging from the sequelae of MI to the toxic effects of drugs on the myocardium. Our understanding of HIV-associated CVD risks has improved greatly over the past decade and a half due to seminal epidemiologic and mechanistic studies.

Epidemiology of HIV-Associated Cardiovascular Diseases

Studies in large cohorts comparing individuals with HIV with individuals without HIV have demonstrated approximately 50% higher risk for MI among individuals with HIV3,9,10. This elevated risk remained after accounting for demographic and clinical confounding variables. Likewise, studies investigating heart failure have demonstrated 50% or higher increased risk among individuals with HIV than among individuals without HIV, even after adjustment for key confounding variables.2,4 Studies also suggest a mildly increased risk for stroke among individuals with HIV11 and a dramatically increased risk for pulmonary hypertension.12

In the early ART era, prolonged exposure to ART was hypothesized as a primary contributor to HIV-associated CVD risks. Indeed, there is some variability in the putative effects of individual antiretroviral drugs on CVD outcomes, including a potential modest effect of abacavir on increasing MI risk.13,14 Nevertheless, more recent data suggest that the effects of ART on CVD are relatively small,15 particularly compared with the problematic effects of uncontrolled HIV. Several studies from large cohorts indicate that HIV viremia and lower CD4+ cell counts are strongly associated with MI and heart failure risk.1-4 Taken together, along with clinical data suggesting that immediate (vs deferred) ART protects against MI,16,17 these data tilt the balance in favor of a net-cardioprotective effect of immediate and continuous ART.1 Of course, immediate and continuous ART remains the cornerstone of HIV therapy. Therefore, from both a CVD prevention standpoint and an overall HIV care standpoint, it is clear that early and continuous ART is essential to optimizing health outcomes for individuals with HIV.

In addition to poor HIV control (ie, with HIV viremia) and immunologic progression (marked by decreasing CD4+ cell count), there are other factors that may increase risk of CVD among individuals with HIV. Metabolic abnormalities, including atherogenic dyslipidemia and body composition changes, are common among individuals with HIV. In the current era, increases in dysfunctional subcutaneous fat and visceral fat have been observed among people with HIV; these changes, in turn, are associated with atherosclerotic plaque.18 Coinfection with hepatitis C virus or cytomegalovirus (CMV) reactivation may also contribute to HIV-associated CVD risk. Individuals with HIV smoke at a significantly higher rate than uninfected individuals; the MI attributable to smoking is considerably higher for...
Mediators of Atherosclerosis and Thrombosis in HIV

Atherosclerosis and thrombosis play central roles in the development of vascular diseases and their clinical manifestations, including MI and stroke. Classically, MIs occur when lipid-rich, inflammatory plaque ruptures or erodes acutely, triggering overlying thrombus and vessel occlusion. In addition to these classic type I MIs, individuals with HIV are at heightened risk for type II MIs, in which myocardial oxygen supply is inadequate relative to demand, triggering myocardial injury.

In this setting, investigators in several studies have observed increased levels of systemic and vascular inflammation, as well as increased platelet activation or aggregation, in individuals with HIV. A common finding across studies of individuals with HIV, as well as monkey models of HIV pathogenesis, is the centrality of inflammation and immune activation to HIV-related CVD risk. Individuals infected with HIV have heightened levels of systemic inflammation and more subclinical atherosclerosis than uninfected individuals. These include elevated levels of soluble CD163 and CD14, as well as common CVD-associated inflammatory markers such as interleukin-6, which are in turn associated with atherosclerosis and mortality. Treatment with ART reduces the levels of several of these markers, but some remain elevated despite ART. Likewise, individuals with HIV have elevated levels of coagulation markers and tissue factor-expressing inflammatory monocytes, creating a functionally procoagulant state that has been associated with clinical thrombosis in HIV.

HIV-Related Cardiovascular Disease Risk Enhancers

Mechanisms of Myocardial Injury

Subclinical Dysfunction and Heart Failure

Figure 1. Conceptual model of the proposed mechanisms of heart failure in HIV. Adapted from Feinstein et al.

Mechanisms and Presentation of HIV-Associated Heart Failure

Causes and presentations of heart failure are heterogeneous in the general population and for individuals with HIV. In the pre-ART era, heart failure was a recognized complication of advanced HIV and marked by viremia and progressive immune compromise, along with global myocardial dysfunction and often inflammation. With widespread uptake of ART, the causes and manifestations of heart failure in individuals with HIV have likewise expanded (Figure 1).

Individuals with persistent HIV viremia, immune progression, and opportunistic infections may still experience HIV-associated cardiomyopathy marked by severe systolic dysfunction in the absence of obstructive coronary artery disease. Furthermore, viremia and immune progression still play a role in less overt cardiomyopathy and heart failure, as each are associated with diastolic dysfunction among individuals with HIV. Yet, with the increasing burden of coronary artery disease and MI among individuals with HIV, ischemic etiologies of heart failure, driven by post-MI myocardial scarring and potential microvascular dysfunction, have become increasingly common. Toxic etiologies of myocardial dysfunction and heart failure also play an outsized role in HIV-related heart failure given the higher rates of myocardial-toxic drug use (eg, methamphetamines) among individuals with HIV.

More subtle manifestations of heart failure in the absence of systolic dysfunction also occur in HIV, as individuals with HIV have higher risks for heart failure with preserved ejection fraction than individuals without HIV. This is likely due to a combination of factors, including but not limited to myocardial inflammation, fibrosis, microvascular ischemia, and myocardial fat deposition. Indeed, several studies using cardiac magnetic resonance imaging, computed tomography, and positron emission tomography have demonstrated that individuals with HIV have more myocardial inflammation, fibrosis, and steatosis than matched control individuals without HIV. These subclinical changes in cardiac tissues are known to be associated with myocardial injury and dysfunction.
Figure 2. A pragmatic approach to atherosclerotic CVD risk stratification, prevention, and therapy for individuals with HIV. Adapted from Feinstein et al and 2018 ACC/AHA guidelines. Abbreviations: ABI, ankle brachial index; ACC, American College of Cardiology; AHA, American Heart Association; apoB, apolipoprotein B-100; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CK, creatine kinase; CVD, cardiovascular disease; D:A:D, Data collection on Adverse events of anti-HIV Drugs; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LFT, liver function test; Lp(a), lipoprotein (a); MI, myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9.
Cardiovascular Disease Risk Stratification, Prevention, and Therapy for Individuals with HIV

Epidemiologic and mechanistic studies have advanced our knowledge of the scope and causes of CVDs in individuals with HIV. However, there are relatively sparse data to practically guide cardiovascular risk stratification, prevention, and treatment for individuals with HIV who are effectively treated with ART. Despite the limitations of these data and absent large-scale trial data for CVD prevention and treatment during effective ART, there are certain consistent findings on HIV-associated CVD risk that may help inform practical approaches.

The clinical data on CVD-preventive strategies among individuals with HIV are relevant in this regard. Over the past 2 decades, numerous small studies have evaluated the effects of statin use on various subclinical markers of inflammation and atherosclerosis for individuals with HIV,21,22 Results of these studies on arterial inflammation have not been consistent, although statins do appear to reduce select inflammatory markers and, as expected, reduce atherogenic lipid levels (eg, low density lipoprotein cholesterol) in individuals with HIV. Questions related to the efficacy of statins in preventing hard atherosclerotic coronary artery disease endpoints in individuals with HIV will be answered with more clarity by the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) study. REPRIEVE randomly assigned individuals with HIV at low to moderate risk for atherosclerotic CVD to pitavastatin or placebo. Enrollment of more than 7500 individuals with HIV is complete and follow-up is ongoing.

Compared with statins, even less clarity exists regarding other potential CVD preventive strategies for individuals with HIV. Ongoing studies (not yet powered for clinical endpoints) are evaluating the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for individuals with HIV. More data are likewise needed related to antithrombotic therapy among individuals with HIV, who have elevated risks for thrombosis. Mechanistic and biomarker studies suggest that aspirin may not be as effective an antplatelet agent for individuals with HIV than for uninfected individuals, but further study and clinical correlations related to aspirin and other antithrombotic therapies in HIV are needed.

Other anti-inflammatory therapies for individuals with HIV are also of interest. These include therapies that target the gut to reduce microbial translocation and gut inflammation, which have not consistently affected biomarkers of inflammation among individuals with HIV. Other therapies tested include canakinumab, an interleukin-1-beta antagonist that reduced inflammatory markers and reduced arterial and bone marrow inflammation in a small study of individuals with HIV, and methotrexate, which did not affect inflammatory markers but modestly reduced CD8+ T-cell counts in individuals with HIV. The efficacy and ultimate clinical applicability of these options remain under investigation.

In the absence of large-scale clinical trial data powered for hard CVD endpoints, interim guidance related to CVD risk stratification, prevention, and treatment for individuals with HIV is based on extrapolation of clinical and mechanistic data. Regarding risk stratification, several studies indicate that traditional CVD risk estimation tools consistently underestimate CVD risk among individuals with HIV. This heightened risk is largely attributable to HIV-related CVD risk-enhancing factors such as prolonged HIV viremia, low current or nadir CD4+ cell count, coinfection (eg, with hepatitis C virus), and the presence of lipid distribution abnormalities. However, for those who are treated promptly and who do not experience these HIV-related risk enhancers, HIV-related increases in CVD risk are modest. Accordingly, the American Heart Association’s scientific statement on HIV-1 recommended adjusting predicted CVD risk upwards by 1.5-fold to 2-fold for individuals with HIV who have HIV-related risk enhancers (Figure 2). In the absence of compelling data otherwise, risk-based approaches to CVD-preventive therapy for individuals with HIV is recommended, with the understanding that as CVD risk increases, the absolute and net benefit of statin therapy for CVD prevention likewise increases.

Conclusion

As life expectancy among individuals with HIV has increased, noncommunicable conditions such as CVDs have become more common for individuals aging with HIV. Several HIV-related factors increase CVD risk, with chronic inflammation and immune dysregulation playing a key role. Limited large-scale clinical trial data exist to guide HIV-specific CVD prevention and therapy, highlighting the importance of further clinical and mechanistic study in this area.

This article was based, in part, on a webcast presented by Dr Matthew J. Feinstein in June 2021: https://youtu.be/CaWqGD9rU. This article was prepared by Dr Feinstein in July 2021.

Financial affiliations with ineligible companies (formerly named “commercial interests” by the Accreditation Council for Continuing Medical Education [ACCME]) in the past 24 months: Dr Feinstein has served on an advisory board for Novartis AG. (Updated September 27, 2021)

References


Perspective

Primary Care Concerns for the Aging Population With HIV

Because individuals with HIV are living longer, comorbidities are moving to the forefront of HIV patient care. People with HIV have a higher risk for HIV-related and non–HIV-related cancers than the general population, making cancer screening vital for this population. Immunizations are another important element of primary care for older adults with HIV, including a COVID-19 vaccine, about which data continue to evolve. This article summarizes a presentation by Steven C. Johnson, MD, at the International Antiviral Society–USA (IAS–USA) virtual HIV course Aging and HIV: Issues, Screening, and Management in Individuals with HIV as They Age in June 2021.

Keywords: HIV, aging, primary care, cancer screening, vaccine, immunization, COVID-19, mortality

Antiretroviral therapy (ART) has improved outcomes for individuals with HIV, and HIV-related deaths have continued to decline (Figure 1).1 In the D:A:D (Data Collection on Adverse Events of Antiretroviral Drugs) study, a reduction in AIDS-related deaths was observed along with improved CD4+ cell counts from 1999 to 2011, although deaths due to non–AIDS-related cancers increased during this period.2 In a study from the Kaiser Permanente group, life expectancy from 2000 to 2016 among individuals with HIV approached that of individuals without HIV; however, those with HIV continued to experience more comorbidities than those who did not have HIV.3 As people with HIV age, primary care becomes an increasingly important element of their care.

Understanding the causes of morbidity and mortality in older people with HIV is central to HIV primary care. Common comorbidities of HIV infection are listed in Table 1. It is incumbent on infectious diseases programs and HIV clinics to develop protocols for screening for common comorbidities in patients with HIV. The US Preventive Services Task Force (USPSTF) and the Infectious Diseases Society of America (IDSA) each provide detailed guidance on screening for people with HIV.4,5 including for various cancers, osteoporosis, and prevention of falls.

Cancer Screening

People with HIV have a higher risk for HIV-related and non–HIV-related cancers than the general population.6 In a study that compared individuals with HIV from 2 separate cohorts with individuals from the Surveillance, Epidemiology, and End Results (SEER) Program from the National Cancer Institute, individuals with HIV had statistically higher levels of various cancers (Table 2).7 Strategies that HIV care clinicians can implement for cancer screening in their patients are shown in Table 3.

Colorectal Cancer

The USPSTF recommends colorectal screening for all adults aged 50 to 75 years (grade A recommendation), as well as for those aged 45 to 49 years (grade B recommendation) and for selected individuals aged 76 to 85 years based on overall health, prior screening, and preferences (grade C recommendation).8 Suggested screening methods include stool-based tests (eg, fetal occult blood or fecal immunochemical test) or direct visualization (eg, computed tomography [CT] colonography, flexible sigmoidoscopy, or colonoscopy).

Lung Cancer

Lung cancer is more common in people with HIV when compared with the general population (Table 2), so adherence to screening guidelines is important. The USPSTF recommends annual lung cancer screening in adults aged 50 to 80 years with a 20 pack-year history of smoking who are current or former (within 15 years) smokers.9 Screening is performed via a low-dose CT scan of the chest. The USPSTF recommends that screening be discontinued after 15 years without smoking, or if the individual develops a health problem that substantially limits life expectancy or the ability and willingness to have curative lung surgery.

Breast and Cervical Cancers

The IDSA recommends breast cancer screening at least every 2 years for individuals with HIV aged 50 to 75 years. They also recommend cervical cancer screening beginning at age 30 years, with a Papanicolaou (Pap)
test at the time of HIV diagnosis and repeated annually, and then every 3 years if results are normal for 3 years consecutively.

### Anal Cancer

People with HIV also have a markedly increased risk of anal cancer. This has led to many programs performing anal cytologic screening and high resolution anoscopy to treat anal dysplasia in an attempt to reduce the incidence of anal cancer. This approach has been recently validated with the results from the ANCHOR (Anal Cancer/HSIL Outcomes Research) study, which is funded by the National Institutes of Health (NIH) and is awaiting publication. This study will likely lead to stronger recommendations regarding anal cytologic screening.

### Immunizations

Immunizations are an important part of primary care for older adults with HIV. The Centers for Disease Control and Prevention (CDC) and the US Department of Health and Human Services provide guidance on appropriate dosing and frequency of available vaccines for individuals with HIV. An immunization schedule by vaccine type and age group is provided in Table 4.

#### Influenza Vaccine

The high-dose influenza vaccine is more immunogenic in individuals aged 65 years and older and in individuals with HIV. Additionally, the high-dose influenza vaccine has been shown to provide better protection against laboratory-confirmed influenza than the standard-dose vaccine. In a study that compared the effectiveness of the high-dose influenza vaccine and the standard-dose vaccine in preventing death, the high-dose vaccine was more effective during the 2012 to 2013 influenza season; however, it was not more effective during the 2013 to 2014 season.

#### COVID-19 Vaccine

Large cohort studies have reported a higher risk of mortality in people with HIV who develop COVID-19. People with HIV often have other comorbidities associated with risk for severe COVID-19, including older age, obesity, cardiovascular disease, lung disease, hypertension, diabetes, and cancer. The CDC has recognized HIV infection as one of the medical conditions that increase risk for severe illness with COVID-19, and in 2021 the organization added a recommendation that everyone who is aged 12 years and older should receive the COVID-19 vaccine. Recent CDC data in the general population indicated the Moderna vaccine to be better than the Pfizer vaccine, which is considered better than Johnson & Johnson, although we do not have comparative data in people with HIV. Of note, people taking ART with well-controlled HIV were included in the phase III trials of the Moderna, Pfizer, and Johnson & Johnson vaccines, but complete data from these trials on immunogenicity, efficacy, and safety in people with HIV are not yet available. Although none of the COVID-19 vaccines currently available are live vaccines, people with HIV who

---

**Table 1. Common Comorbidities in Older Individuals With HIV**

<table>
<thead>
<tr>
<th>Comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol use</td>
</tr>
<tr>
<td>Bipolar disorder</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Drug use</td>
</tr>
<tr>
<td>Heart disease</td>
</tr>
<tr>
<td>Hepatitis B</td>
</tr>
<tr>
<td>Hepatitis C</td>
</tr>
<tr>
<td>Human papillomavirus infection, syphilis, and other sexually transmitted infections</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Non–AIDS-related cancers</td>
</tr>
<tr>
<td>Osteoporosis</td>
</tr>
<tr>
<td>Tobacco use</td>
</tr>
<tr>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>

**Table 2. Relative Risk of Cancer in Individuals With HIV Compared With the General Population**

<table>
<thead>
<tr>
<th>Type of Cancer</th>
<th>Standardized rate ratio (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anal cancer</td>
<td>42.9 (34.1 – 53.3)</td>
</tr>
<tr>
<td>Vaginal cancer</td>
<td>21 (11.2 – 35.9)</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>14.7 (11.6 – 18.2)</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>7.7 (5.7 – 10.1)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>3.3 (2.8 – 3.9)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>2.6 (1.9 – 3.6)</td>
</tr>
<tr>
<td>Oropharyngeal cancer</td>
<td>2.6 (1.9 – 3.4)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2.5 (1.6 – 3.8)</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>2.3 (1.8 – 2.9)</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>1.8 (0.4 – 0.8)</td>
</tr>
</tbody>
</table>

Adapted from Patel et al.

**Table 3. Strategies for Cancer Screening and Prevention in an HIV Program**

<table>
<thead>
<tr>
<th>Type of cancer</th>
<th>Prevention strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>Tobacco counseling, low-dose chest computed tomography scanning</td>
</tr>
<tr>
<td>Oral</td>
<td>Oral exam</td>
</tr>
<tr>
<td>Anal</td>
<td>Rectal exam, anal cytology</td>
</tr>
<tr>
<td>Prostate</td>
<td>Rectal exam, prostate-specific antigen testing discussion</td>
</tr>
<tr>
<td>Cervical</td>
<td>Pelvic exam, cervical cytology, human papillomavirus testing</td>
</tr>
<tr>
<td>Colorectal</td>
<td>Rectal exam, fecal occult blood testing, colonoscopy</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Periodic skin exam, sun exposure counseling</td>
</tr>
<tr>
<td>Liver</td>
<td>Hepatitis B vaccine, hepatitis B and C treatment if applicable, abdominal ultrasound, computed tomography scan for surveillance</td>
</tr>
</tbody>
</table>

---

Adapted from Table 2.
are taking ART and have CD4+ cell counts in normal ranges respond well to live vaccines, so there is potential for this to hold true with COVID-19 vaccines in the future. People with HIV who have advanced disease and are immunocompromised may have a reduced response to vaccines but are also at greater risk for severe COVID-19. For patients with advanced HIV infection (e.g., CD4+ cell count <200 cells/µL) or untreated HIV infection, a third dose of the mRNA vaccine is recommended at least 28 days after the receipt of the first 2 doses of either of the mRNA vaccines. People with HIV are now eligible for boosters of the COVID-19 vaccine 6 months after the primary series of the mRNA vaccines or 2 months after the primary immunization with the Johnson & Johnson vaccine. The booster can either be the same vaccine previously received (a homologous booster) or a different COVID-19 vaccine (a heterologous booster).

Summary

Life expectancy continues to improve for people with HIV, but comorbidities continue to play a large role in morbidity and mortality, making primary care crucial for this population. Many of the USPSTF recommendations are particularly important for older people with HIV, including updated guidelines for lung and colorectal cancer screening. Immunizations are also important in older people with HIV, with the role of COVID-19 vaccination continuing to evolve as more data become available.

References


Categories of Articles

**Perspectives.** Perspective articles are summaries of selected talks given at IAS–USA continuing medical education courses. The lecture content is peer reviewed prior to presentation by at least 2 reviewers. An IAS–USA medical writer prepares a summary manuscript from a transcript of the talk. The manuscript is reviewed and edited by the presenter and the journal’s appointed peer reviewer(s).

**Reviews.** Topics in Antiviral Medicine™ welcomes original review articles on current issues related to infection with HIV or other viruses. Topics in Antiviral Medicine™ does not publish original research. Manuscripts should be 3000 to 6000 words (excluding references, tables, and figures) and should include numbered references and a brief introductory abstract of approximately 100 to 200 words. Original, adapted, or reprinted figures and tables may be included and should be cited in the text and accompanied by a brief title. Adapted and reprinted work requires proof of permission obtained from the original publishers and authors. Authors interested in submitting unsolicited manuscripts are encouraged to submit an outline or abstract of the proposed manuscript first, please contact the editor for further information.

**Editorials.** Topics in Antiviral Medicine™ invites submission of editorials. Editorials should be approximately 500 to 1500 words (excluding references) and should include numbered references.

**Special Contributions.** A special contribution article often represents the unique contribution (such as a consensus statement) of an author or group of authors.

**Cases From the Field.** Topics in Antiviral Medicine™ invites submission of case reports accompanied by a scholarly literature review of the topic. Each case report should be 1500 to 3000 words (excluding references, tables, and figures), include numbered references, and seek to teach an important lesson for HIV or viral hepatitis care practitioners.

**Stories.** Stories for the Telling Stories column share the experiences of those involved in the care of people infected with HIV or other viruses. Stories may be approximately 800 to 3500 words; submissions are welcome for consideration.

**Commentaries.** Discussion on a current issue in the management of viral diseases is welcome as a Commentary. Commentaries should be 500 to 1500 words and include numbered references as appropriate. Commentaries may be invited by the editors; unsolicited submissions are also welcome for consideration.

**Letters to the Editor.** Letters to the editor are welcome and should be sent to the address listed below. Please limit letters to 500 words.

**Special Issues.** Topics in Antiviral Medicine™ often publishes issues with a special focus, such as summaries of IAS–USA continuing medical education courses and reports from scientific meetings.

**Reprints.** Reprints of articles by expert panels convened by the IAS–USA are included periodically in Topics in Antiviral Medicine™.

Submission of Manuscripts

Manuscripts should be submitted via mail or email to the address below. Each author should complete an Authorship Form, which is available online at https://iasusa.org/activities/topics-in-antiviral-medicine/tam-policies-practices/tam-author-and-contributor-guidelines/ or may be obtained by contacting the editor at the address below. Outlines or abstracts of proposed manuscripts are welcome and may be sent via mail or email.

**Editor.** Topics in Antiviral Medicine™
IAS–USA
131 Steuart St, Ste 500
San Francisco, CA 94105

Email: journal@iasusa.org

Receipt of submitted manuscripts will be acknowledged by editorial staff, and submissions will be reviewed by peer reviewers. Acceptance for publication is based on the quality and relevance of the work.

Copyright

Copyright to all manuscripts and graphics published in Topics in Antiviral Medicine™ is owned by the IAS–USA unless noted otherwise. All authors and contributors of manuscripts accepted for publication, with the exception of US federal government employees, must sign a copyright transfer form as a condition of publication.

Authorship Requirements

Topics in Antiviral Medicine™ uses the definition of authorship formulated by the International Committee of Medical Journal Editors and published in its Uniform Requirements for Manuscripts Submitted to Biomedical Journals. This definition states that authorship “be based on the following 4 criteria: (1) Substantial contributions to the conception or design of the work; (2) drafting the work or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved... acquisition of funding; general supervision of a research group or general administrative support; and writing assistance do not constitute authorship. Topics in Antiviral Medicine™ will not consider ghostwritten articles for publication.

Financial Disclosure

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All authors and contributors to Topics in Antiviral Medicine™ are required to disclose any financial relationships with ineligible companies within the past 24 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount, and defines an ineligible company as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion, which includes review by at least 1 reviewer who has no financial relationships with ineligible companies.